Generics in France
Published: August 2013 · Publisher: MarketLine
Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017).
- Description
- Companies Mentioned
- Table of Contents
- Ask a Question
Introduction
Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The French generics market had total revenues of $4.5bn in 2012, representing a compound annual growth rate (CAGR) of 7.2% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 10.1% between 2008-2012, to reach a total of 42.7% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 5.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in France
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the France economy
Key Questions Answered
What was the size of the France generics market by value in 2012?
What will be the size of the France generics market in 2017?
What factors are affecting the strength of competition in the France generics market?
How has the market performed over the last five years?
What are the main segments that make up France's generics market?
Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the France generics market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
*The French generics market had total revenues of $4.5bn in 2012, representing a compound annual growth rate (CAGR) of 7.2% between 2008 and 2012.
*Market consumption volume increased with a CAGR of 10.1% between 2008-2012, to reach a total of 42.7% of total pharma volume in 2012.
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 5.2% for the five-year period 2012 - 2017, which is expected to drive the market to a value of $5.8bn by the end of 2017.
Features
Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in France
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
Leading company profiles reveal details of key generics market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume
Macroeconomic indicators provide insight into general trends within the France economy
Key Questions Answered
What was the size of the France generics market by value in 2012?
What will be the size of the France generics market in 2017?
What factors are affecting the strength of competition in the France generics market?
How has the market performed over the last five years?
What are the main segments that make up France's generics market?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
Biogaran S.A.S., Mylan Inc., Sandoz International GmbH and Sanofi
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Threat of substitutes 19
Degree of rivalry 20
Leading Companies 21
Biogaran S.A.S. 21
Mylan Inc. 22
Sandoz International GmbH 25
Sanofi 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: France generics market value: $ million, 2008–12 9
Table 2: France generics market volume: % of total pharma volume, 2008–12 10
Table 3: France generics market geography segmentation: $ million, 2012 11
Table 4: France generics market value forecast: $ million, 2012–17 12
Table 5: France generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Biogaran S.A.S.: key facts 21
Table 7: Mylan Inc.: key facts 22
Table 8: Mylan Inc.: key financials ($) 22
Table 9: Mylan Inc.: key financial ratios 23
Table 10: Sandoz International GmbH: key facts 25
Table 11: Sanofi: key facts 26
Table 12: Sanofi: key financials ($) 27
Table 13: Sanofi: key financials (€) 27
Table 14: Sanofi: key financial ratios 27
Table 15: France size of population (million), 2008–12 29
Table 16: France gdp (constant 2000 prices, $ billion), 2008–12 29
Table 17: France gdp (current prices, $ billion), 2008–12 29
Table 18: France inflation, 2008–12 30
Table 19: France consumer price index (absolute), 2008–12 30
Table 20: France exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: France generics market value: $ million, 2008–12 9
Figure 2: France generics market volume: % of total pharma volume, 2008–12 10
Figure 3: France generics market geography segmentation: % share, by value, 2012 11
Figure 4: France generics market value forecast: $ million, 2012–17 12
Figure 5: France generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in France, 2012 14
Figure 7: Drivers of buyer power in the generics market in France, 2012 16
Figure 8: Drivers of supplier power in the generics market in France, 2012 17
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2012 18
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2012 19
Figure 11: Drivers of degree of rivalry in the generics market in France, 2012 20
Figure 12: Mylan Inc.: revenues & profitability 23
Figure 13: Mylan Inc.: assets & liabilities 24
Figure 14: Sanofi: revenues & profitability 28
Figure 15: Sanofi: assets & liabilities 28
Executive Summary 2
Market value 2
Market value forecast 2
Market volume 2
Market volume forecast 2
Geography segmentation 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 9
Market value 9
Market volume 10
Market Segmentation 11
Geography segmentation 11
Market Outlook 12
Market value forecast 12
Market volume forecast 13
Five Forces Analysis 14
Summary 14
Buyer power 16
Supplier power 17
New entrants 18
Threat of substitutes 19
Degree of rivalry 20
Leading Companies 21
Biogaran S.A.S. 21
Mylan Inc. 22
Sandoz International GmbH 25
Sanofi 26
Macroeconomic Indicators 29
Country Data 29
Appendix 31
Methodology 31
Industry associations 32
Related research 32
LIST OF TABLES
Table 1: France generics market value: $ million, 2008–12 9
Table 2: France generics market volume: % of total pharma volume, 2008–12 10
Table 3: France generics market geography segmentation: $ million, 2012 11
Table 4: France generics market value forecast: $ million, 2012–17 12
Table 5: France generics market volume forecast: % of total pharma volume, 2012–17 13
Table 6: Biogaran S.A.S.: key facts 21
Table 7: Mylan Inc.: key facts 22
Table 8: Mylan Inc.: key financials ($) 22
Table 9: Mylan Inc.: key financial ratios 23
Table 10: Sandoz International GmbH: key facts 25
Table 11: Sanofi: key facts 26
Table 12: Sanofi: key financials ($) 27
Table 13: Sanofi: key financials (€) 27
Table 14: Sanofi: key financial ratios 27
Table 15: France size of population (million), 2008–12 29
Table 16: France gdp (constant 2000 prices, $ billion), 2008–12 29
Table 17: France gdp (current prices, $ billion), 2008–12 29
Table 18: France inflation, 2008–12 30
Table 19: France consumer price index (absolute), 2008–12 30
Table 20: France exchange rate, 2008–12 30
LIST OF FIGURES
Figure 1: France generics market value: $ million, 2008–12 9
Figure 2: France generics market volume: % of total pharma volume, 2008–12 10
Figure 3: France generics market geography segmentation: % share, by value, 2012 11
Figure 4: France generics market value forecast: $ million, 2012–17 12
Figure 5: France generics market volume forecast: % of total pharma volume, 2012–17 13
Figure 6: Forces driving competition in the generics market in France, 2012 14
Figure 7: Drivers of buyer power in the generics market in France, 2012 16
Figure 8: Drivers of supplier power in the generics market in France, 2012 17
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2012 18
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2012 19
Figure 11: Drivers of degree of rivalry in the generics market in France, 2012 20
Figure 12: Mylan Inc.: revenues & profitability 23
Figure 13: Mylan Inc.: assets & liabilities 24
Figure 14: Sanofi: revenues & profitability 28
Figure 15: Sanofi: assets & liabilities 28
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.